Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on January 6, 2026 reporting Item 7.01 (Regulation FD Disclosure). Denali provided a 2026 program update and milestone timeline in a January 6 press release.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Denali provided a 2026 program update and milestone timeline in a January 6 press release
- Company confirmed participation in 44th Annual J.P. Morgan Healthcare Conference, indicating engagement with investors
- Update likely outlines key development progress and catalysts for the year ahead, important for valuation and timing of potential value inflections
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.